Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -0.71 Increased by +35.45% | -0.60 Decreased by -30.56% |
| Mar 9, 23 | -0.58 Increased by +25.64% | -0.59 Increased by +2.87% |
| Nov 7, 22 | -0.65 Increased by +4.41% | -0.65 |
| Aug 4, 22 | -0.93 Decreased by -50.00% | -0.78 Decreased by -24.65% |
| May 9, 22 | -1.10 Decreased by -89.66% | -0.75 Decreased by -62.22% |
| Feb 24, 22 | -0.78 Decreased by -105.26% | -0.66 Decreased by -27.55% |
| Nov 10, 21 | -0.68 Decreased by -41.67% | -0.62 Decreased by -15.61% |
| Aug 10, 21 | -0.62 Increased by +44.14% | -0.60 Decreased by -5.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -26.77 M Increased by +37.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -22.10 M Increased by +26.82% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -24.89 M Increased by +4.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -35.87 M Decreased by -51.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -42.57 M Decreased by -108.06% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -30.20 M Decreased by -58.29% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -25.99 M Decreased by -54.78% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -23.63 M Decreased by -53.65% | Decreased by N/A% Decreased by N/A% |
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.